JPRN-jRCT1080223359未知2 期
A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects with Visual Acuity Impairment Associated with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
试验速览
- 阶段
- 2 期
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 <= 90age old（—）
- 性别
- All
入选标准
- •Participant is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures. Participant has met criteria of the surgery center anti coagulation protocol, if applicable
- •- Confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) confirmed within 28 days prior to initial randomization by the central reading center using fundus photographs and including the following;
- •a) The study eyes must have at least 1 GA lesion that involves the fovea, and a Macular Photocoagulation Study (MPS) disc areas (DA) of >= 1 and <= 7 (1 Macular Photocoagulation Study Disc Area (MPS DA equivalent to 2.54 millimeter (mm)^2 on the retina) determined by screening images of fundus autofluorescence photographs as calculated by the reading center. If GA is multifocal, at least 1 lesion must be >= 0.5 DA,
- •b) GA must be able to be photographed in its entirety and may be contiguous with peripapillary atrophy,
- •c) Retinal photographs, fundus autofluorescence images, and angiography of sufficient quality, allowing assessment of the macular area according to standard clinical practice, can be obtained
- •d) The imaging center must be able to delineate and confirm peripapillary atrophy with fundus photography and fundus autofluorescence,
- •e) Images must include the central field 1, 2, and 3 field images as defined by the University of Wisconsin standards as well as a supero temporal image to capture the subretinal injection area if possible
- •- Female participants must be postmenopausal with last menses 12 months prior, or longer without medical reasons (example, treatment with a drug), or a measured follicle stimulating hormone >= 26 milliinternational units per milliliter (mIU/mL)
- •- Study eyes will have a best corrected visual acuity (BCVA) of 20/80 to 20/800 (Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR value 0.6-1.6). BCVA in the study eye must be worse than the BCVA in the fellow eye at screening
- •- Male participants must be sterile or willing to use 2 approved methods of contraception from first day postoperatively to 3 months postoperatively
排除标准
- •- Participant has a history of neovascular (wet) AMD in the study eye, including any evidence of retinal pigment epithelium rips or evidence of subretinal or choroidal neovascularization. History or evidence of neovascular AMD in the fellow eye is allowed, if antivascular endothelial growth factor (VEGF) therapy has not been required for at least 8 weeks prior to screening
- •- A diagnosis of glaucoma with an intraocular pressure (IOP) >= 25 millimeter of mercury (mm Hg) while being treated with an ocular hypotensive drug. Treatment should be no more than 1 drug preparation/combination, which can contain 1 or 2 ocular hypotensive active ingredients; participants receiving more than 2 ocular hypotensive active ingredients are excluded
- •- Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above Grade 2 per Age Related Eye Disease Study (AREDS) scale or any other ophthalmologic condition that reduces the clarity of the media that, in the opinion of the investigator or reading center, interferes with ophthalmologic examination (example, corneal abnormalities, inadequate pupillary dilation)
- •- Myopia >-8 diopters and participants with >4 diopters of astigmatism, and >+10 diopters of hyperopia
- •- Previous vitrectomy, retinal detachment repair, submacular surgery, other surgical interventions targeting AMD, scleral buckling or glaucoma filtration surgery or any other extraocular or orbital procedure in the study eye that, in the opinion of the surgeon, would hamper the suprachoroidal cannulation procedure in the study eye
研究者
相似试验
尚未招募
2 期
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck CancerOral MucositisHead and Neck CancerCancer - Head and neckOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620000540910PSI CRO Australia Pty. Ltd.110
进行中（未招募）
1 期
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyEUCTR2024-000203-67-Outside-EU/EEAKadmon Corporation, LLC
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-FRGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
不适用
A study to determine the safety and efficacy of Laptinib in combination with Vinorelbine or Capecitabine in Women with ErbB2-Overexpressing Metastatic Breast Cancer.Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2009-009885-15-BGGlaxoSmithKline Research & Development Ltd105
进行中（未招募）
1 期
A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast CancerBreast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer)MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-009885-15-GRGlaxoSmithKline Research & Development Ltd105